Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Stanford University
Fred Hutchinson Cancer Center
MedImmune LLC
Massachusetts General Hospital